The Clinical Neuroproteomics Research Unit participates in the project financed by the Michael J. Fox Foundation together with the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), the Institute of Neurosciences of the University of Barcelona, the Valdecilla Research Institute (IDIVAL) and the Biodonostia Health Research Institute.
Several genes have been identified whose mutations can trigger the onset of Parkinson's disease (PD). It is estimated that mutations in the gene coding for the LRRK2 protein are responsible for approximately 3% of cases presenting the disease. In this multicentre project, we are pursuing an exhaustive characterisation of the molecular alterations that accompany the mutational profile of LRRK2, with the aim of identifying both markers of progression and new therapeutic targets.
